152 related articles for article (PubMed ID: 11072786)
1. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
3. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
[TBL] [Abstract][Full Text] [Related]
4. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
5. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
6. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
8. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
[TBL] [Abstract][Full Text] [Related]
9. Steroidal aromatase inhibitors in elderly patients.
Bajetta E; Zilembo N; Bichisao E; Pozzi P; Toffolatti L
Crit Rev Oncol Hematol; 2000 Feb; 33(2):137-42. PubMed ID: 10737375
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
11. Formestane as treatment of advanced breast cancer in elderly women.
Zilembo N; Buzzoni R; Celio L; Noberasco C; Ferrari L; Laffranchi A; Vicario G; Dolci S; Bajetta E
Tumori; 1994 Dec; 80(6):433-7. PubMed ID: 7900232
[TBL] [Abstract][Full Text] [Related]
12. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
[TBL] [Abstract][Full Text] [Related]
14. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
15. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience.
Gironés R; Torregrosa D; Díaz-Beveridge R
Crit Rev Oncol Hematol; 2010 Mar; 73(3):236-45. PubMed ID: 19748793
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of formestane in breast cancer patients.
Lønning PE; Geisler J; Johannessen DC; Gschwind HP; Waldmeier F; Schneider W; Galli B; Winkler T; Blum W; Kriemler HP; Miller WR; Faigle JW
J Steroid Biochem Mol Biol; 2001 Apr; 77(1):39-47. PubMed ID: 11358673
[TBL] [Abstract][Full Text] [Related]
18. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
Dowsett M
Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
[TBL] [Abstract][Full Text] [Related]
20. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Carlini P; Ferretti G; Di Cosimo S; Colella E; Tonachella R; Romiti A; Tomao S; Frassoldati A; Papaldo P; Fabi A; Ruggeri EM; Cognetti F
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):107-9. PubMed ID: 12943750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
